Roche invests in prenatal screening tests

Publié le 2 Déc, 2014

Roche has announced the take-over of Arizona Diagnostics, Inc., a company based in San Jose (California, United States), which markets non-invasive prenatal tests.

 

These blood tests are carried out from the 10th week of pregnancy in an attempt to diagnose the risk of Patau’s syndrome, Edwards’s syndrome and Down syndrome.

 

Throughout the world, there are over 200 million births each year and “prenatal screening for Down syndrome has become current practice”.

Pharmacy Times 02/12/2014 – Global Post 02/12/2014

Share this post

[supsystic-social-sharing id='1']
Recevez notre lettre hebdomadaire

Recevez notre lettre hebdomadaire

Chaque semaine notre décryptage de l'actualité bioéthique et revue de presse.

Votre inscription a bien été prise en compte.